You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteolytic Imaging of Remodeling Myocardium

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Mitochondrial Antioxidant Neurodegenerative Therapeutics: XJB-5-131 Derivatives

    SBC: SOLANO PHARMACEUTICALS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Oxidative damage to mitochondrial is a major source of toxicity in diseases such as Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD). Mitochondria are energy powerhouses of the cell, and decline in their function by oxidative damage is a common feature among neurodegenerative diseases. Despite years of effort, however, generic ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. CardioPort to Enable Intracardiac Beating Heart and Minimally Invasive Open Heart Surgery

    SBC: Nido Surgical, Inc            Topic: NHLBI

    DESCRIPTIONprovided by applicantThe goal of this Fast Track STTR project is to develop a novel CardioPortTM surgical device that will enable minimally invasive beating heart repair without use of cardiopulmonary bypassCPBThere is a critical unmet need for new instruments to improve the surgical repair of heart defects in childrenCurrent best surgical practices involve either open heart surgery wit ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: Protein Metrics Inc.            Topic: 300

    DESCRIPTION provided by applicant This project addresses the need for better methods for deciphering the glycosylation of proteins in clinical samples Glycosylation is an important modifier of protein structure and function and contributes to disease processes But we currently know little about the glycosylation of most proteins The current methods for probing glycans on proteins are not su ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Screening the Ribosome for New Target Sites

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. T SS needle protein inhibitors for the treatment of P aeruginosa infection

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant Bacterial resistance to lactam antibiotics is threatening to limit the effectiveness of this most used class of antibiotics A major contributin factor to this problem is the lack of rapid testing methods for medical practitioners to identify lactam resistant pathogens before prescribing specific antibiotics For urinary tract infections UTIs the most c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government